Germline mutations in retinoblastoma 1 (RB1) and ionizing radiation are the major risk factors for the development of osteosarcoma. We have recently demonstrated that normal bone cells sustaining radiation injury enter a state of permanent proliferative arrest known as cellular senescence. 1 This state is associated with the secretion of a large panel of growth factor and cytokines, including interleukin (IL)-6, that reinforce senescence in an autocrine/paracrine fashion. Interestingly, these mediators also recruit various components of the immune system including natural killer T (NKT) cells, are play a prominent role in cancer immunosurveillance. Altogether, the soluble mediators released by senescent bone cells and the immune effector cells they recruit contribute to tumor suppression upon the exposure of osteoblasts to carcinogenic doses of ionizing radiation in vivo (Fig. 1) .
Our findings add to a wealth of data linking senescence, once thought to be a purely cell-autonomous oncosuppressive process like apoptosis, to cancer immunosurveillance. In osteosarcoma cell lines, the reintroduction of functional RB1 results in a permanent cell cycle exit and senescence. Senescence is also induced in normal cells by the ectopic expression of oncogenes. Generally, this results not only in a definite growth arrest, but also in the release of a large panel of bioactive molecules, a process referred to as "senescenceassociated secretory phenotype" (SASP). Our data place these observations into a context that go beyond radiation-induced osteosarcoma formation.
Another interesting implication of our findings relates to the in vivo model systems that are available for the study of osteosarcoma. These generally include xenograft models, whereby human cell lines are implanted into immunocompromised mice, genetically engineered or carcinogen-induced murine models, and large canine breeds, in which spontaneous osteosarcoma is relatively common. 2 The use of xenografts is associated with obvious limitations, especially in an era in which the contribution of the immune system to the efficacy of anticancer therapy is being increasingly recognized. Genetically engineered mouse models come in 2 flavors: those in which an oncogene (e.g., Fos) is activated, 3 and those in which one or more oncosuppressor gene(s) (e.g., Rb1 or Trp53) are deleted, in both cases either conditionally within osteoblasts or at the whole-body level. 4 Since we have shown that the deletion of Rb1 abrogates senescence as induced in osteoblasts by carcinogenic stimuli, and presumably also by ectopic oncogene activation, murine osteosarcoma modes based on the inactivation of Trp53, either alone or together with Rb1, probably fail to engage the immune system in the way we observed in our study. It is difficult to know how this relates to human osteosarcoma. However, a limited fraction of osteosarcoma cases have been documented in families with the Li-Fraumeni syndrome (bearing germline mutations in TP53) or familial retinoblastoma (bearing germline mutations in RB1).
Moreover, we found that the SASP and RB1 expression correlate with improved clinical outcome in patients affected by primary osteosarcomas, most of whom have not been exposed to ionizing radiation. Taken together, these observations suggest that murine models of The mechanisms by which retinoblastoma 1 (rB1) mediates oncosuppressive functions are still being elucidated. we found that radiation-induced senescence in the bone depends on rB1 and is associated with the secretion of multiple bioactive factors, including interleukin-6 (IL-6), as well as with the infiltration of natural killer T (NKT) cells. Importantly, the inhibition of rB1, IL-6 or NKT cells predisposed mice to radiation-induced osteosarcomas, unveiling a cancer cellextrinsic mechanisms that underlie the oncosuppressive activity of rB1.
osteosarcoma driven by the deletion of key genes involved in senescence may not recapitulate the immunological aspects of the human disease.
The molecular circuitries that underpin the complex features of senescence are not well understood. The spectrum of bioactive molecules released by a given cell undergoing senescence is dependent not only on tissue type but also on the initiating insult. In the irradiated bone, RB1 promotes the expression of IL-1β, IL-6, IL-8, KIT ligand (KITLG), FAS, chemokine (C-C motif) ligand 2 (CCL2), CCL20, and tumor necrosis factor receptor superfamily, member 11B (TNFRSF11B, best known as OPG). The genes coding for all these mediators are direct targets of the transcription factor NF-κB. RB1 has previously been shown to activate NF-κB, although we did not test this in our paper. 5 In addition, the inhibition of NF-κB appears to delay DNA damageinduced senescence in aging mice. 6 In the bone, RB1 is likely to play a role in the E2F-mediated repression of genes controlling cellular proliferation as well as in the activation of NF-κB-regulated SASPunderlying genes, thus promoting senescence and the activation of an immune response.
IL-6 is a key component of the SASP response to irradiation. IL-6 is known to exert pro-and antitumor functions, dependent on tumor type and stage. 7 We propose that the immediate response of osteoblasts to genotoxic stress results in the RB1-dependent secretion of IL-6, which mediates antineoplastic effects early in osteosarcoma development as it reinforces senescence and alerts the immune system. IL-8 and chemokine (C-X-C motif) ligand 2 (CXCL2, also known as MIP2) are also upregulated by irradiation and have been shown to reinforce senescence as part of a positive feedback loop that amplifies the DNA damage response. 8 We demonstrated that exogenous recombinant IL-6 can restore the senescent response of RB1-deficient cells exposed to radiation ex vivo. In mice, IL-6 regulates the trafficking of NKT cells in a paracrine manner. We also propose that the introduction of IL-6 into an IL-6-naïve microenvironment may act as an adjuvant to stimulate antitumor immune responses. Indeed, the growth of IL-6-deficient osteosarcomas was suppressed when these tumors were implanted into wild-type mice. Similarly, the administration of exogenous IL-6 may also activate antitumor immune responses to osteosarcoma. Increased IL-6 expression has been correlated with infection and inflammation following surgery, and in osteosarcoma patients post-operative infections are associated with improved survival. 9 Liposomal muramyl tripeptide phosphatidylethanolamine (mifamurtide, trade name Mepact ® ) is currently approved for the treatment of non-metastatic osteosarcoma. This synthetic analog of the mycobacterial cell wall is a non-specific immunostimulatory agent. The administration of mifamurtide is also associated with an increased secretion of several cytokines including IL-6. 10 Our results suggest that the RB1-mediated release of IL-6 in response to radiation promotes senescence and the recruitment of NKT cells, which contribute to cancer immunosurveillance. These findings extend our understanding on the oncosuppressive functions of RB1, and link them to emerging therapeutic opportunities whereby immunomodulators may play an important role against the development and progression of osteosarcoma.
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